Kallman v. Aronchick
981 F. Supp. 2d 372
E.D. Pa.2013Background
- Plaintiffs Murial and Stanley Kallman (New Jersey residents) sued Salix Pharmaceuticals, InKine, and Dr. Craig Aronchick alleging Murial developed Stage 4 kidney disease after taking OsmoPrep prescribed and ingested in New Jersey.
- Plaintiffs filed in Philadelphia Court of Common Pleas; Salix and InKine removed to the Eastern District of Pennsylvania based on diversity, asserting Dr. Aronchick (a Pennsylvania resident) was not properly joined/served or was fraudulently joined.
- Plaintiffs’ Amended Complaint asserts multiple claims under theories including strict liability, failure to warn, negligence, and NJ Product Liability Act (NJPLA) causes of action; Plaintiffs sought to plead under both New Jersey and Pennsylvania law.
- The Court conducted a choice-of-law analysis and concluded New Jersey substantive law governs the claims because the prescription, filling, ingestion, and plaintiffs’ residence are in New Jersey.
- The Court held Dr. Aronchick was fraudulently joined because NJPLA governs product-harm claims and it imposes liability only on manufacturers/sellers (not inventors/consultants/royalty recipients); thus claims against Dr. Aronchick were insubstantial under New Jersey law.
- Because dismissal of Dr. Aronchick defeated venue in the Eastern District of Pennsylvania, the Court denied remand, dismissed Dr. Aronchick, and transferred the case to the District of New Jersey; pending motions to dismiss were denied without prejudice to refile in New Jersey.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Choice of law: which state law governs substantive claims | Kallman pleaded both NJ and PA claims and sought discovery before choosing law | Defendants argued NJ law applies given contacts where drug was prescribed, filled, and ingested | Court applied Pennsylvania choice-of-law framework and held New Jersey law governs (stronger contacts and interests) |
| Fraudulent joinder of non-diverse defendant (Dr. Aronchick) | Kallman: Aronchick was inventor/researcher/consultant/royalty recipient and thus can be held liable for product harm | Defendants: Under NJPLA, liability is limited to manufacturers/sellers; Aronchick is not such an entity so joinder is frivolous | Court held joinder was fraudulent — claims against Aronchick were wholly insubstantial under NJ law; Aronchick dismissed |
| Effect of NJPLA on common-law claims | Kallman: asserted negligence and warranty theories among others | Defendants: NJPLA subsumes product-harm claims; negligence/warranty (except express warranty) not separate remedies | Court held NJPLA is exclusive remedy for product-caused harm, limiting viable claims to manufacturing defect, failure to warn, or design defect |
| Venue after dismissal of forum defendant | Plaintiffs sought remand to state court | Defendants removed and sought to retain federal forum; court must assess proper venue under § 1391/§ 1404 | Court concluded E.D. Pa. is not proper venue after dismissing PA defendant and transferred case to the District of New Jersey under § 1404(a) in the interest of justice |
Key Cases Cited
- Abels v. State Farm Fire & Cas. Co., 770 F.2d 26 (3d Cir. 1985) (federal courts should not perform choice-of-law analysis at fraudulent-joinder stage if plaintiff’s choice is colorable)
- Batoff v. State Farm Ins. Co., 977 F.2d 848 (3d Cir. 1992) (standard and burden for establishing fraudulent joinder; pleadings assumed true)
- In re Briscoe, 448 F.3d 201 (3d Cir. 2006) (court may disregard nondiverse defendant’s citizenship if joinder is fraudulent and retain jurisdiction)
- Hammersmith v. TIG Ins. Co., 480 F.3d 220 (3d Cir. 2007) (Pennsylvania choice-of-law framework and real/true-conflict analysis)
- Jumara v. State Farm Ins. Co., 55 F.3d 873 (3d Cir. 1995) (private and public interest factors for § 1404(a) transfer analysis)
- Repola v. Morbark Indus., Inc., 934 F.2d 483 (3d Cir. 1991) (NJPLA creates exclusive statutory cause of action for product claims)